Global GLP-1 Receptor Antagonist Market Growth 2024-2030

Global GLP-1 Receptor Antagonist Market Growth 2024-2030

GLP-1 receptor antagonists are a class of drugs used to treat metabolic diseases such as type 2 diabetes and obesity. They act on the GLP-1 receptor and inhibit the binding of GLP-1 to its receptor, thus blocking the biological effects of GLP-1. These drugs reduce insulin secretion by reducing the effects of GLP-1 and are often used to control blood sugar levels and weight. GLP-1 receptor antagonists are the opposite of GLP-1 receptor agonists, which are drugs that stimulate GLP-1 receptors and promote the biological effects of GLP-1.

The global GLP-1 Receptor Antagonist market size is projected to grow from US$ 3696 million in 2024 to US$ 5557 million in 2030; it is expected to grow at a CAGR of 7.0% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “GLP-1 Receptor Antagonist Industry Forecast” looks at past sales and reviews total world GLP-1 Receptor Antagonist sales in 2023, providing a comprehensive analysis by region and market sector of projected GLP-1 Receptor Antagonist sales for 2024 through 2030. With GLP-1 Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Receptor Antagonist industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Receptor Antagonist market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Receptor Antagonist.

From the perspective of market size and growth trends, the GLP-1 drug market is growing rapidly. It has achieved great success in sales due to its excellent patient compliance. Take dulaglutide and semaglutide as examples. The global sales of these two drugs in 2022 will reach US$7.44 billion and US$9.342 billion respectively. In addition, the market value of two major pharmaceutical companies, Novo Nordisk and Eli Lilly, has soared due to the popularity of GLP-1 drugs. In the diabetes drug market, GLP-1 drugs have a market share of 39%, surpassing insulin to become the largest type of diabetes treatment drug in the world. In general, the market for GLP-1 receptor antagonists (or GLP-1 receptor agonists) is developing rapidly, and long-acting and oral administration are the main development trends in the future.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Injection
Oral Agent

Segmentation by Application:
Diabetes Treatment
Research
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
AstraZeneca
Sanofi
Eli Lilly
Bayer
Merck
Shionogi
Pfizer
Jiangsu Hengrui Pharmaceuticals
Shanghai Fosun Pharmaceutical (Group)
Shanghai Pharmaceutical Industry Research Institute

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 Receptor Antagonist market?

What factors are driving GLP-1 Receptor Antagonist market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1 Receptor Antagonist market opportunities vary by end market size?

How does GLP-1 Receptor Antagonist break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.